Stoke Therapeutics vs Tonix Pharmaceuticals Holding
Stoke Therapeutics is the larger business, with $184m of revenue in fiscal 2025 against $13.1m for Tonix Pharmaceuticals Holding (14.1 times as much). Stoke Therapeutics grew faster (404.5% against 29.8%). Stoke Therapeutics kept more of each dollar of sales as profit: a net margin of -3.7% against -946.2%.
| Latest fiscal year | Stoke TherapeuticsSTOK, 2025 | Tonix Pharmaceuticals HoldingTNXP, 2025 |
|---|---|---|
| Revenue | $184m | $13.1m |
| Revenue growth | 404.5% | 29.8% |
| Net income | −$6.9m | −$124m |
| Operating margin | -11.2% | — |
| Net margin | -3.7% | -946.2% |
| Return on equity | -2.4% | -64.5% |
| Free cash flow | $44.9m | −$103m |
| Cash | $84.2m | $208m |
| Total debt | $0 | — |
| Debt to equity | 0.0% | — |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | $13.8m |
| Employees | 170 | 142 |
| Market value | $1.69bn | $86.9m |
| Price vs our value range | — | — |
| Moat score | — | — |
| Insider trades, 12 months | 0 buys, 83 sales | 7 buys, 0 sales |